


Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-Dec-2023  
Document Type: USP Monographs  
DocId: GUID-5E45E63C-C24E-447F-864E-DF717D37781F\_3\_en-US  
DOI: https://doi.org/10.31003/USPNF\_M35850\_03\_01  
DOI Ref: 8a734

© 2025 USPC  
Do not distribute

# Gramicidin



| Gramicidin | X <sub>1</sub> | X <sub>2</sub> | Molecular formula                                                 | Molecular weight |
|------------|----------------|----------------|-------------------------------------------------------------------|------------------|
| A1         | V              | W              | C <sub>99</sub> H <sub>140</sub> N <sub>20</sub> O <sub>17</sub>  | 1882.33          |
| A2         | I              | W              | C <sub>100</sub> H <sub>142</sub> N <sub>20</sub> O <sub>17</sub> | 1896.36          |
| B1         | V              | F              | C <sub>97</sub> H <sub>139</sub> N <sub>19</sub> O <sub>17</sub>  | 1843.30          |
| C1         | V              | Y              | C <sub>97</sub> H <sub>139</sub> N <sub>19</sub> O <sub>18</sub>  | 1859.29          |
| C2         | I              | Y              | C <sub>98</sub> H <sub>141</sub> N <sub>19</sub> O <sub>18</sub>  | 1873.32          |

Gramicidin  
CAS RN<sup>®</sup>: 1405-97-6; UNII: 5IE62321P4.

**DEFINITION**  
Gramicidin is an antibacterial substance produced by the growth of *Bacillus brevis* Dubos (Fam. Bacillaceae). It may be obtained from tyrothricin. It has a potency of NLT 900 µg of gramicidin per mg, calculated on the dried basis.

**IDENTIFICATION**  
*Delete the following:*  
▲• [SPECTROSCOPIC IDENTIFICATION TESTS, \(197\)Ultraviolet-Visible Spectroscopy](#).▲ (USP 1-Dec-2023)  
*Add the following:*  
▲• A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\), Infrared Spectroscopy](#): 197K.▲ (USP 1-Dec-2023)  
*Add the following:*  
▲• B. The retention times of the major peaks of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the test for *Composition*.▲ (USP 1-Dec-2023)

**ASSAY**  
*Change to read:*  
• [ANTIBIOTICS—MICROBIAL ASSAYS \(81\)](#): ▲Determine the median concentration (S3), starting with the concentration suggested in [\(81\)](#), [Table 7](#), to obtain the optimum concentration—response relationship.▲ (USP 1-Dec-2023)  
**Acceptance criteria:** It has a potency of NLT 900 µg of gramicidin per mg calculated on the dried basis.

**IMPURITIES**  
• [RESIDUE ON IGNITION \(281\)](#): NMT 1.0%, the charred residue being moistened with 2 mL of [nitric acid](#) and 5 drops of [sulfuric acid](#)  
*Add the following:*  
▲• **ORGANIC IMPURITIES**  
**Mobile phase:** Methanol and [water](#) (71:29)  
**Sensitivity solution:** 2 µg/mL of [USP Gramicidin RS](#) in *Mobile phase*  
**Standard solution:** 1 mg/mL of [USP Gramicidin RS](#) in *Mobile phase*  
**Sample solution:** 1 mg/mL of Gramicidin in *Mobile phase*

Chromatographic system

(See [Chromatography \(621\), System Suitability.](#))

Mode: LC

Detector: UV 282 nm

Column: 4.6-mm × 25-cm; 5-μm packing [L1](#)

Column temperature: 50°

Flow rate: 1.0 mL/min

Injection volume: 20 μL

System suitability

Samples: *Sensitivity solution* and *Standard solution*

[NOTE—The relative retention times in [Table 1](#) are provided as information that could aid in peak assignment.]

Table 1

| Name                       | Relative Retention Time |
|----------------------------|-------------------------|
| Gramicidin C1 <sup>a</sup> | 0.7                     |
| Gramicidin C2 <sup>b</sup> | 0.8                     |
| Gramicidin A1 <sup>c</sup> | 1.0                     |
| Gramicidin A2 <sup>d</sup> | 1.2                     |
| Gramicidin B1 <sup>e</sup> | 1.9                     |

- <sup>a</sup> N-Formyl-L-valylglycyl-L-alanyl-D-leucyl-L-alanyl-D-valyl-L-valyl-D-valyl-L-tryptophyl-D-leucyl-L-tyrosyl-D-leucyl-L-tryptophyl-D-leucyl-N-(2-hydroxyethyl)-L-tryptophanamide.
- <sup>b</sup> N-Formyl-L-isoleucylglycyl-L-alanyl-D-leucyl-L-alanyl-D-valyl-L-valyl-D-valyl-L-tryptophyl-D-leucyl-L-tyrosyl-D-leucyl-L-tryptophyl-D-leucyl-N-(2-hydroxyethyl)-L-tryptophanamide.
- <sup>c</sup> N-Formyl-L-valylglycyl-L-alanyl-D-leucyl-L-alanyl-D-valyl-L-valyl-D-valyl-L-tryptophyl-D-leucyl-L-tryptophyl-D-leucyl-L-tryptophyl-D-leucyl-N-(2-hydroxyethyl)-L-tryptophanamide.
- <sup>d</sup> N-Formyl-L-isoleucylglycyl-L-alanyl-D-leucyl-L-alanyl-D-valyl-L-valyl-D-valyl-L-tryptophyl-D-leucyl-L-tryptophyl-D-leucyl-L-tryptophyl-D-leucyl-N-(2-hydroxyethyl)-L-tryptophanamide.
- <sup>e</sup> N-Formyl-L-valylglycyl-L-alanyl-D-leucyl-L-alanyl-D-valyl-L-valyl-D-valyl-L-tryptophyl-D-leucyl-L-phenylalanyl-D-leucyl-L-tryptophyl-D-leucyl-N-(2-hydroxyethyl)-L-tryptophanamide.

Suitability requirements

Resolution: NLT 1.5 between gramicidin A1 and gramicidin A2, *Standard solution*

Signal-to-noise ratio: NLT 10 for the gramicidin A1 peak, *Sensitivity solution*

Analysis

Sample: *Sample solution*

Calculate the percentage of each impurity peak (the peak other than gramicidins A1, A2, B1, C1, and C2):

Result =  $(r_U/r_T) \times 100$

$r_U$  = peak response of the individual impurity

$r_T$  = total response of all the peaks

Acceptance criteria: Disregard any impurity with a peak area less than that of gramicidin A1 in the *Sensitivity solution*. NMT 1 impurity exceeds 1.0%.

Any individual impurity: NMT 2.0▲ (USP 1-Dec-2023)

SPECIFIC TESTS

- **MELTING RANGE OR TEMPERATURE** (741), *Procedures, Procedure for Class Ia*: NLT 229°, determined after drying
- **CRYSTALLINITY** (695): Meets the requirements
- **LOSS ON DRYING** (731).

**Sample:** About 100 mg

**Analysis:** Dry the *Sample* in a capillary-stoppered bottle in vacuum at 60° for 3 h.

**Acceptance criteria:** NMT 3.0%

Add the following:

▲ • COMPOSITION

**Mobile phase, Sensitivity solution, Standard solution, Sample solution, Chromatographic system, and System suitability:** Proceed as directed in the *Organic Impurities*.

Analysis

**Sample:** *Sample solution*

Calculate the percentage of each of the components (gramicidins A1, A2, B1, C1, and C2):

$$\text{Result} = (r_U/r_T) \times 100$$

$r_U$  = peak response of the individual component

$r_T$  = total response of all the peaks

**Acceptance criteria:** See [Table 2](#).

Table 2

| Name                                                                    | Acceptance Criteria         |
|-------------------------------------------------------------------------|-----------------------------|
| Ratio of gramicidin A1 to the sum of gramicidins A1, A2, B1, C1, and C2 | NLT 0.60                    |
| Sum of gramicidins A1, A2, B1, C1, and C2                               | NLT 95.0%▲ (USP 1-Dec-2023) |

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.
- **USP REFERENCE STANDARDS** (11).  
[USP Gramicidin RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact                                                              | Expert Committee                              |
|----------------|----------------------------------------------------------------------|-----------------------------------------------|
| GRAMICIDIN     | <a href="#">Julie Zhang</a><br>Associate Science & Standards Liaison | BIO42020 Biologics Monographs 4 - Antibiotics |

**Chromatographic Database Information:** [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 50(2)

**Current DocID:** GUID-5E45E63C-C24E-447F-864E-DF717D37781F\_3\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M35850\\_03\\_01](https://doi.org/10.31003/USPNF_M35850_03_01)

**DOI ref:** [8a734](#)